CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%
Clinical safety rating: safe
May enhance the effects of neuromuscular blocking agents Causes severe and sometimes fatal Clostridium difficile-associated diarrhea.
Inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, suppressing peptide bond formation.
| Metabolism | Primarily hepatic via CYP3A4; metabolites include clindamycin sulfoxide and N-demethylclindamycin. |
| Excretion | Approximately 10% of administered dose excreted renally as active drug; significant biliary/fecal elimination (about 40% as active drug and metabolites) via enterohepatic circulation. |
| Half-life | Terminal elimination half-life is 2.4–3.0 hours in adults with normal hepatic and renal function; prolonged in severe hepatic impairment (up to 8–10 hours) and in neonates (8–20 hours). |
| Protein binding | 93–96% bound primarily to albumin. |
| Volume of Distribution | 0.6–1.2 L/kg (total body water); extensive distribution to most tissues except CNS (penetrates poorly into CSF even with inflamed meninges). |
| Bioavailability | Oral: ~87–90% (fasting); IM: ~87–100% (complete). Topical: minimal systemic absorption (<5% with intact skin). |
| Onset of Action | IV: Rapid, within minutes for antibacterial effect. IM: 1–3 hours to reach peak serum concentrations. Topical: 2–4 weeks for clinical improvement in acne. Oral: 1–2 hours. |
| Duration of Action | IV/IM: Serum levels above MIC for 6–8 hours with typical dosing intervals. Topical: After discontinuation, effects persist for weeks due to suppression of Cutibacterium acnes. |
600-900 mg IV every 8 hours, or 900 mg IV every 12 hours.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required for GFR ≥10 mL/min; for GFR <10 mL/min and anuric patients, give full dose every 8-12 hours or consider reducing dose by 50%. |
| Liver impairment | No specific guidelines; use caution in severe hepatic impairment (Child-Pugh C) and monitor liver function. |
| Pediatric use | Neonates: 15-20 mg/kg/day IV divided every 6-8 hours; Infants and children: 20-40 mg/kg/day IV divided every 6-8 hours, up to 40 mg/kg/day for severe infections. |
| Geriatric use | No specific dose adjustment; monitor renal function and for adverse effects due to age-related decline in renal clearance. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
May enhance the effects of neuromuscular blocking agents Causes severe and sometimes fatal Clostridium difficile-associated diarrhea.
| FDA category | Human |
| Breastfeeding | Clindamycin is excreted into human breast milk in low levels (M/P ratio approximately 0.3-0.7). Limited data suggest it is compatible with breastfeeding, but may cause gastrointestinal effects (diarrhea, thrush) in the infant. Use with caution, especially in preterm or ill infants. |
| Teratogenic Risk |
■ FDA Black Box Warning
Can cause severe and sometimes fatal colitis, including pseudomembranous colitis, due to Clostridioides difficile overgrowth.
| Common Effects | Diarrhea (including C. difficile) |
| Serious Effects |
Hypersensitivity to clindamycin, lincomycin, or any component; history of antibiotic-associated colitis.
| Precautions | Monitor for antibiotic-associated colitis; use with caution in patients with gastrointestinal disease, hepatic impairment, and history of asthma or allergies. |
Loading safety data…
| Clindamycin is classified as FDA Pregnancy Category B. No evidence of teratogenicity in animal studies, but adequate human studies in pregnant women are lacking. Use only if clearly needed, especially in the first trimester. There is a potential risk of pseudomembranous colitis in the neonate if administered near term. |
| Fetal Monitoring | Monitor maternal liver function, renal function, and complete blood count periodically, especially with prolonged therapy. Observe for signs of pseudomembranous colitis. For neonate, monitor for diarrhea, thrush, or signs of gastrointestinal disturbance. |
| Fertility Effects | No known adverse effects on fertility in animal studies. Human data insufficient to determine impact on fertility. |